Aldosterone antagonists in the treatment of poorly controlled and resistant arterial hypertension – results of the newest PATHWAY-2 trial Review article
Article Sidebar
Main Article Content
Abstract
Treatment of hypertension in many cases requires the use of several antihypertensive agents. Current guidelines determine in which groups of patients specific groups of antihypertensive drugs should be preferred, they also give recommendations on particular combinations of 2 antihypertensive agents. PATHWAY-2 study was the first study to establish a treatment algorithm in patients with resistant hypertension and to define the place of spironolactone in the treatment. The present paper summarizes the current state of knowledge on these issues.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Zdrojewski T., Bandosz P., Rutkowski M. et al.: Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętniczego w Polsce – wyniki badania NATPOL 2011. Nadciśnienie Tętnicze 2014; 18: 116-117.
3. Sim J.J., Bhandari S.K., Shi J. et al.: Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin. Proc. 2013; 88(10): 1099-1107.
4. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N. et al.: Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch. Intern. Med. 2008; 168(11): 1159-1164.
5. Calhoun D.A., Nishizaka M.K., Zaman M.A. et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40(6): 892-896.
6. Pimenta E., Gaddam K.K., Oparil S. et al.: Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54(3): 475-481.
7. Williams B., MacDonald T., Brown M.; on behalf of the PATHWAY Investigators: Optimal Treatment of Drug Resistant Hypertension PATHWAY-2 Principal Results. ESC Congress, London 2015.
8. Williams B., MacDonald T.M., Caulfield M.: Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open 2015; 5(8): e008951.